These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 16396772

  • 1. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A.
    Leuk Lymphoma; 2006 Mar; 47(3):481-5. PubMed ID: 16396772
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F.
    Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
    [Abstract] [Full Text] [Related]

  • 3. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC.
    J Clin Oncol; 2003 Feb 01; 21(3):514-9. PubMed ID: 12560443
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep 01; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 01; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pegfilgrastim.
    Curran MP, Goa KL.
    Drugs; 2002 Sep 01; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F.
    Br J Haematol; 1998 Dec 01; 103(3):678-83. PubMed ID: 9858216
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G.
    Anticancer Drugs; 2003 Apr 01; 14(4):259-64. PubMed ID: 12679729
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J.
    Clin Lung Cancer; 2016 Mar 01; 17(2):119-27. PubMed ID: 26781346
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB, Kido A.
    Clin Pharmacokinet; 2011 May 01; 50(5):295-306. PubMed ID: 21456630
    [Abstract] [Full Text] [Related]

  • 20. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
    Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A.
    BMC Cancer; 2008 Jul 10; 8():195. PubMed ID: 18616811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.